News
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (T reg) therapies for ...
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the ...
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (T reg) therapies for ...
Regulatory T cell-focused Sonoma Biotherapeutics has been following a slow and steady path ever since bringing in a whopping $265 million in a 2021 fundraising round, one of the largest of the year.
Hosted on MSN9mon
Seattle’s Sonoma Biotherapeutics receives $45M milestone paymentSonoma Biotherapeutics on Wednesday announced that it received a $45 million payment from Regeneron Pharmaceuticals for meeting a significant milestone in its efforts to research, develop and ...
SOUTH SAN FRANCISCO, Calif. & SEATTLE, May 06, 2025--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg ...
Regeneron and Sonoma Biotherapeutics have announced a partnership to identify and develop regulatory T cell (Treg) therapies for autoimmune diseases. Treg cells work by surveying the body for unwanted ...
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sonoma Biotherapeutics, Inc. Tuesday announced partnership to discover, develop and sell T cell therapies for autoimmune diseases. As per the ...
SOUTH SAN FRANCISCO, Calif. & SEATTLE, May 13, 2025--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg ...
Sonoma Biotherapeutics Announces Oral and Poster Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Sonoma Biotherapeutics, Inc., a clinical-stage ...
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results